Profile data is unavailable for this security.
About the company
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.
- Revenue in USD (TTM)12.20m
- Net income in USD-104.41m
- Incorporated2018
- Employees175.00
- LocationTScan Therapeutics Inc880 Winter StreetWALTHAM 02451United StatesUSA
- Phone+1 (857) 399-9500
- Fax+1 (302) 531-3150
- Websitehttps://www.tscan.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abeona Therapeutics Inc | 0.00 | -52.60m | 264.43m | 84.00 | -- | 3.47 | -- | -- | -2.13 | -2.13 | 0.00 | 1.76 | 0.00 | -- | -- | 0.00 | -56.09 | -53.22 | -65.23 | -65.81 | -- | -- | -- | -1,894.25 | -- | -- | 0.2004 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Kodiak Sciences Inc | 0.00 | -197.68m | 267.28m | 111.00 | -- | 1.25 | -- | -- | -3.77 | -3.77 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -39.89 | -31.73 | -44.14 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Mersana Therapeutics Inc | 29.94m | -104.77m | 269.89m | 123.00 | -- | 32.03 | -- | 9.02 | -0.8648 | -0.8648 | 0.2469 | 0.0687 | 0.1222 | -- | 38.14 | 243,390.30 | -42.75 | -61.68 | -59.36 | -81.35 | -- | -- | -349.98 | -622.19 | -- | -- | 0.7508 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Fate Therapeutics Inc | 12.32m | -175.72m | 271.03m | 181.00 | -- | 0.6826 | -- | 22.00 | -1.71 | -1.71 | 0.1185 | 3.49 | 0.0221 | -- | 6.35 | 68,049.73 | -31.56 | -31.82 | -33.99 | -36.05 | -- | -- | -1,426.67 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -88.51m | 274.08m | 20.00 | -- | -- | -- | -- | -2.52 | -2.52 | 0.00 | -0.2208 | 0.00 | -- | -- | 0.00 | -77.89 | -38.44 | -81.83 | -39.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 54.16 | -- | -- | -- |
| Pyxis Oncology Inc | 16.15m | -59.20m | 274.53m | 51.00 | -- | 1.60 | -- | 17.00 | -1.26 | -1.26 | 0.3269 | 2.88 | 0.0842 | -- | -- | 322,920.00 | -30.87 | -- | -33.12 | -- | 97.06 | -- | -366.67 | -- | -- | -- | 0.0008 | -- | -- | -- | 38.87 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -174.01m | 281.13m | 75.00 | -- | 0.6134 | -- | -- | -2.07 | -2.07 | 0.00 | 5.43 | 0.00 | -- | -- | 0.00 | -31.67 | -5.90 | -32.99 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -44.80m | 282.55m | 10.00 | -- | 3.33 | -- | -- | -0.7538 | -0.7538 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -33.86 | -36.79 | -39.67 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1522 | -- | -- | -- | 39.47 | -- | -- | -- |
| ADC Therapeutics SA | 70.72m | -212.15m | 283.30m | 273.00 | -- | -- | -- | 4.01 | -2.40 | -2.40 | 0.7742 | -1.78 | 0.1733 | 0.2987 | 3.13 | 259,036.60 | -51.13 | -48.41 | -62.27 | -55.63 | 91.81 | -- | -295.00 | -308.62 | 4.68 | -3.92 | 1.65 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Tscan Therapeutics Inc | 12.20m | -104.41m | 287.12m | 175.00 | -- | 1.12 | -- | 23.53 | -1.05 | -1.05 | 0.1225 | 4.82 | 0.0353 | -- | -- | 79,220.78 | -30.19 | -- | -33.78 | -- | -- | -- | -855.84 | -- | -- | -- | 0.1066 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Zura Bio Ltd | 0.00 | -42.62m | 288.90m | 14.00 | -- | 1.93 | -- | -- | -0.5807 | -0.5807 | 0.00 | 2.34 | 0.00 | -- | -- | 0.00 | -32.18 | -- | -43.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Biomea Fusion Inc | 0.00 | -144.01m | 290.27m | 107.00 | -- | 3.82 | -- | -- | -4.00 | -4.00 | 0.00 | 2.10 | 0.00 | -- | -- | 0.00 | -85.85 | -- | -98.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| aTyr Pharma Inc | 235.00k | -63.82m | 292.96m | 56.00 | -- | 4.05 | -- | 1,246.63 | -0.9365 | -0.9365 | 0.0034 | 0.8617 | 0.0022 | -- | 0.12 | 4,196.43 | -58.90 | -45.45 | -67.15 | -52.74 | -- | -- | -27,155.32 | -784.19 | -- | -- | 0.0233 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Ocugen Inc | 8.19m | -45.87m | 293.61m | 65.00 | -- | 15.51 | -- | 35.85 | -0.1785 | -0.1785 | 0.0319 | 0.0658 | 0.1265 | -- | -- | 126,015.40 | -78.54 | -83.56 | -103.70 | -97.79 | -- | -- | -620.91 | -2,921.94 | -- | -- | 0.1445 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| AC Immune SA | 46.48m | -45.22m | 302.76m | 133.00 | -- | 2.06 | -- | 6.51 | -0.4634 | -0.4634 | 0.481 | 1.49 | 0.2116 | -- | 3.19 | 349,481.20 | -20.59 | -18.25 | -29.04 | -19.52 | -- | -- | -97.29 | -148.29 | -- | -14.57 | 0.0231 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
Data as of Nov 13 2024. Currency figures normalised to TScan Therapeutics Inc's reporting currency: US Dollar USD
60.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Lynx1 Capital Management LPas of 30 Jun 2024 | 5.22m | 10.73% |
| EcoR1 Capital, LLCas of 30 Jun 2024 | 5.00m | 10.27% |
| Adage Capital Management LPas of 30 Jun 2024 | 4.40m | 9.04% |
| BVF Partners LPas of 30 Jun 2024 | 2.99m | 6.14% |
| Baker Bros. Advisors LPas of 30 Jun 2024 | 2.78m | 5.72% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 2.19m | 4.49% |
| Propel Bio Management LLCas of 30 Jun 2024 | 2.09m | 4.29% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.07m | 4.25% |
| BlackRock Advisors LLCas of 30 Jun 2024 | 1.86m | 3.82% |
| Simplify Asset Management, Inc.as of 30 Sep 2024 | 1.05m | 2.15% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
